Amira Barkal, MD, PhDPrincipal Founder and Interim CEO at Pheast Therapeutics
Dr. Amira Barkal, MD, PhD, is Principal Founder and Interim CEO at Pheast Therapeutics, an immuno-oncology company founded in 2020 with origins in Irv Weissman’s lab at Stanford University. Dr. Barkal received her MD and PhD in Stem Cell Biology and Regenerative Medicine in the Medical Scientist Training Program at Stanford University School of Medicine in 2021. She completed her doctoral thesis in the laboratory of Professor Irving Weissman, where she studied mechanisms of macrophage tumor immunosurveillance and led the discovery that CD24 is a novel innate immune checkpoint in cancer. She is a leader in the field of innate immunity in cancer, and conducts research aimed at understanding the regulators of intratumoral macrophage function. Dr. Barkal also holds a position as Resident Physician in Internal Medicine at Brigham and Women’s Hospital at Harvard Medical School. She is a recipient of the Ruth L. Kirschstein Fellowship of the National Cancer Institute, the Harold M. Weintraub Award, and the Society of Immunotherapy of Cancer Young Investigator Award.